- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03103087
LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
LIBERTY 2: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Co-Administered With and Without Low-Dose Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Study Overview
Status
Conditions
Detailed Description
This study is an international phase 3 randomized, double-blind, placebo-controlled efficacy and safety study to evaluate 24 weeks of oral daily relugolix 40 mg co-administered with low-dose E2 and NETA (Group A) and 12 weeks of daily oral relugolix 40 mg alone followed by 12 weeks of daily oral relugolix 40 mg co-administered with low-dose E2 and NETA (Group B) compared with 24 weeks of placebo (Group C).
All participants completing the Week 24 visit, including participants randomized to placebo, were offered the opportunity to enroll in an open-label extension study in which all eligible participants will receive relugolix co-administered with low-dose E2 and NETA. Participants who did not enroll into the extension study had a follow-up visit approximately 30 days after the end of treatment (that is, after the participant's last dose of study medication).
Safety will be assessed throughout the study by monitoring adverse events, vital signs, physical examinations, clinical laboratory tests, 12-lead electrocardiograms, and assessments of bone mineral density.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Brussels, Belgium, 1070
- Brussels
-
Brussels, Belgium, 1200
- Brussels
-
Ghent, Belgium, 9000
- Ghent
-
Jette, Belgium, 1090
- Jette
-
La Louvière, Belgium, 7100
- La Louvière
-
-
-
-
-
Botucatu, Brazil, 18618-686
- Botucatu
-
Porto Alegre, Brazil, 90510-040
- Porto Alegre
-
Porto Alegre, Brazil, 90035-903
- Porto Alegre
-
São Paulo, Brazil, 04266-010
- Sao Paulo
-
-
-
-
-
San Ramón, Chile, 8880465
- San Ramon
-
Santiago, Chile, 8320165
- Santiago
-
Santiago, Chile, 8360160
- Santiago
-
-
Providencia
-
Santiago, Providencia, Chile, 7510186
- Santiago
-
-
-
-
-
Jihlava, Czechia, 586 33
- Jihlava
-
Náchod, Czechia, 54701
- Náchod
-
Olomouc, Czechia, 772 00
- Olomouc
-
Ostrava, Czechia, 708 52
- Ostrava
-
Písek, Czechia, 39701
- Písek
-
České Budějovice, Czechia, 370 01
- České Budějovice
-
-
-
-
-
Budapest, Hungary, 1106
- Budapest
-
Debrecen, Hungary, 4025
- Debrecen
-
Gyula, Hungary, 5700
- Gyula
-
Kecskemét, Hungary, 6000
- Kecskemét
-
Pécs, Hungary, 7624
- Pecs
-
Szentes, Hungary, 6600
- Szentes
-
-
Hajdu
-
Debrecen, Hajdu, Hungary, 4032
- Debrecen
-
-
Szabolcs-Szatmar-Bereg
-
Nyíregyháza, Szabolcs-Szatmar-Bereg, Hungary, 4400
- Nyíregyháza
-
-
-
-
-
Gdańsk, Poland, 80850
- Gdańsk
-
-
Malopolskie
-
Krakow, Malopolskie, Poland, 30114
- Kraków
-
-
Mazowieckie
-
Rzeszów, Mazowieckie, Poland, 35302
- Rzeszów
-
-
Podlaskie
-
Białystok, Podlaskie, Poland, 15224
- Białystok
-
Białystok, Podlaskie, Poland, 15464
- Bialystok
-
-
Slaskie
-
Katowice, Slaskie, Poland, 40724
- Katowice
-
-
Wielkopolskie
-
Poznań, Wielkopolskie, Poland, 60-192
- Poznan
-
-
-
-
-
Bloemfontein, South Africa, 9301
- Bloemfontein
-
Centurion, South Africa, 00157
- Centurion
-
Parow, South Africa, 7500
- Parow
-
-
Western Cape
-
Cape Town, Western Cape, South Africa, 7405
- Cape Town
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35205
- Birmingham
-
-
Arizona
-
Mesa, Arizona, United States, 85209
- Mesa
-
Tucson, Arizona, United States, 85704
- Tucson
-
Tucson, Arizona, United States, 85712
- Tuscon
-
-
California
-
Canoga Park, California, United States, 91303
- Canoga Park
-
Huntington Beach, California, United States, 92647
- Huntington Beach
-
Long Beach, California, United States, 90806
- Long Beach
-
Los Angeles, California, United States, 90036
- Los Angeles
-
Los Angeles, California, United States, 90057
- Los Angeles
-
Panorama City, California, United States, 91402
- Panorama
-
San Diego, California, United States, 92114
- San Diego
-
Upland, California, United States, 91786
- Upland
-
-
Colorado
-
Denver, Colorado, United States, 80209
- Denver
-
Lakewood, Colorado, United States, 80228
- Lakewood
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20036
- Washington
-
-
Florida
-
Aventura, Florida, United States, 33180
- Aventura
-
DeLand, Florida, United States, 32720
- Deland
-
Fort Lauderdale, Florida, United States, 33316
- Ft. Lauderdale
-
Jupiter, Florida, United States, 33458
- Jupiter
-
Lake City, Florida, United States, 32055
- Lake City
-
Loxahatchee Groves, Florida, United States, 33470
- Loxahachee
-
Miami, Florida, United States, 33126
- Miami
-
Miami, Florida, United States, 33155
- Miami
-
Miami Springs, Florida, United States, 33166
- Miami Springs
-
New Port Richey, Florida, United States, 34652
- New Port Richey
-
North Miami, Florida, United States, 33161
- North Miami
-
Oviedo, Florida, United States, 32765
- Oviedo
-
Plantation, Florida, United States, 33324
- Plantation
-
Port Saint Lucie, Florida, United States, 34952
- Port St. Lucie
-
Saint Cloud, Florida, United States, 34769
- Saint Cloud
-
Sarasota, Florida, United States, 34239
- Sarasota
-
Stuart, Florida, United States, 34996
- Stuart
-
Tampa, Florida, United States, 33606
- Tampa
-
Wellington, Florida, United States, 33414
- Wellington
-
West Palm Beach, Florida, United States, 33409
- West Palm Beach
-
-
Georgia
-
Atlanta, Georgia, United States, 30312
- Atlanta
-
Decatur, Georgia, United States, 30034
- Decatur
-
Duluth, Georgia, United States, 30097
- Duluth
-
Norcross, Georgia, United States, 30093
- Norcross
-
Sandy Springs, Georgia, United States, 30328
- Sandy Springs
-
Savannah, Georgia, United States, 31406
- Savannah
-
-
Idaho
-
Idaho Falls, Idaho, United States, 83404
- Idaho Falls
-
Nampa, Idaho, United States, 83686
- Nampa
-
-
Illinois
-
Champaign, Illinois, United States, 61820
- Champaign
-
Chicago, Illinois, United States, 60611
- Chicago
-
Naperville, Illinois, United States, 60540
- Naperville
-
Oak Brook, Illinois, United States, 60523
- Oakbrook
-
-
Indiana
-
Avon, Indiana, United States, 46123
- Avon
-
-
Kansas
-
Shawnee Mission, Kansas, United States, 66128
- Shawnee
-
-
Louisiana
-
Marrero, Louisiana, United States, 70072
- Marrero
-
Metairie, Louisiana, United States, 70006
- Metairie
-
New Orleans, Louisiana, United States, 70115
- New Orleans
-
-
Maryland
-
Baltimore, Maryland, United States, 21208
- Baltimore
-
Towson, Maryland, United States, 21204
- Towson
-
-
Michigan
-
Bay City, Michigan, United States, 48706
- Bay City
-
Canton, Michigan, United States, 48187
- Canton
-
Detroit, Michigan, United States, 48201
- Detroit
-
Saginaw, Michigan, United States, 48604
- Saginaw
-
-
Nebraska
-
Norfolk, Nebraska, United States, 68701
- Norfolk
-
-
Nevada
-
Las Vegas, Nevada, United States, 89113
- Las Vegas
-
Las Vegas, Nevada, United States, 89106
- Las Vegas
-
Las Vegas, Nevada, United States, 89109
- Las Vegas
-
-
New Jersey
-
New Brunswick, New Jersey, United States, 08901
- New Brunswick
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87102
- Albuquerque
-
-
New York
-
Brooklyn, New York, United States, 11201
- Brooklyn
-
New York, New York, United States, 10038
- New York
-
New York, New York, United States, 10022
- New York
-
Rochester, New York, United States, 14642
- Rochester
-
-
North Carolina
-
Durham, North Carolina, United States, 27713
- Durham
-
Raleigh, North Carolina, United States, 27607
- Raleigh
-
Winston-Salem, North Carolina, United States, 27103
- Winston Salem
-
-
Ohio
-
Cincinnati, Ohio, United States, 45212
- Cincinnati
-
Columbus, Ohio, United States, 43231
- Columbus
-
-
Pennsylvania
-
West Reading, Pennsylvania, United States, 19611
- West Reading
-
-
South Carolina
-
Charleston, South Carolina, United States, 29406
- Charleston
-
-
Texas
-
Beaumont, Texas, United States, 77702
- Beaumont
-
Dallas, Texas, United States, 75231
- Dallas
-
Dallas, Texas, United States, 75234
- Dallas
-
Fort Worth, Texas, United States, 76104
- Fort Worth
-
Frisco, Texas, United States, 75035
- Frisco
-
Houston, Texas, United States, 77030
- Houston
-
Houston, Texas, United States, 77054
- Houston
-
Longview, Texas, United States, 75605
- Longview
-
San Antonio, Texas, United States, 78258
- San Antonio
-
-
Virginia
-
Norfolk, Virginia, United States, 23502
- Virginia Beach
-
Richmond, Virginia, United States, 23225
- Richmond
-
-
Washington
-
Covington, Washington, United States, 98042
- Covington
-
Puyallup, Washington, United States, 98372
- Puyallup
-
Spokane, Washington, United States, 99207
- Spokane
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Key Inclusion Criteria:
- Premenopausal female aged 18 to 50 years old (inclusive) on the day of signing and dating the informed consent form.
- Has regularly occurring menstrual periods of ≤ 14 days duration with a cycle of 21 to 38 days from the start of 1 menstrual period until the start of the next, by participant history for at least 3 months prior to the first screening visit.
- Has a diagnosis of uterine fibroids that is confirmed by a transvaginal and/or transabdominal ultrasound performed during the screening period.
- Has heavy menstrual bleeding associated with uterine fibroids as evidenced by an MBL of ≥ 160 milliliter (mL) during 1 cycle or ≥ 80 mL per cycle for 2 menstrual cycles as measured by the alkaline hematin method during the screening period.
Key Exclusion Criteria:
- Has transvaginal and/or transabdominal ultrasound during the screening period demonstrating pathology other than uterine fibroids that could be responsible for or contributing to the participant's heavy menstrual bleeding.
- Has known rapidly enlarging uterine fibroids in the opinion of the investigator.
- Has a weight that exceeds the weight limit of the DXA scanner or has a condition that precludes an adequate DXA measurement at the lumbar spine and proximal femur.
- Has a history of or currently has osteoporosis, or other metabolic bone disease, hyperparathyroidism, hyperprolactinemia, hyperthyroidism, anorexia nervosa, or low traumatic (from the standing position) or atraumatic fracture (toe, finger, skull, face and ankle fractures are allowed). A history of successfully treated hyperparathyroidism, hyperprolactinemia, or hyperthyroidism is allowed if the participant's bone mineral density is within normal limits.
- Has a history of the use of bisphosphonates, calcitonin, calcitriol, ipriflavone, teriparatide, denosumab, or any medication other than calcium and vitamin D preparations to treat bone mineral density loss.
- Has been a participant in an investigational drug or device study within the 1 month prior to the first screening visit.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Relugolix plus E2/NETA (Group A)
Relugolix co-administered with E2/NETA for 24 weeks.
|
Relugolix (40 mg) tablet administered orally once daily.
Other Names:
E2 (1.0 mg)/NETA (0.5 mg) co-formulated capsule administered orally once daily.
Other Names:
|
EXPERIMENTAL: Relugolix plus Delayed E2/NETA (Group B)
Relugolix co-administered with E2/NETA placebo for 12 weeks, followed by relugolix co-administered with E2/NETA for 12 weeks.
|
Relugolix (40 mg) tablet administered orally once daily.
Other Names:
E2 (1.0 mg)/NETA (0.5 mg) co-formulated capsule administered orally once daily.
Other Names:
E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the capsule containing E2/NETA in size, shape, color, and odor.
Other Names:
|
PLACEBO_COMPARATOR: Placebo (Group C)
Relugolix placebo co-administered with E2/NETA placebo for 24 weeks.
|
Relugolix (0 mg) placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.
E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the capsule containing E2/NETA in size, shape, color, and odor.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage Of Participants Who Achieved A Menstrual Blood Loss (MBL) Volume Of < 80 mL And A ≥ 50% Reduction From Baseline MBL Volume With Relugolix Plus E2/NETA
Time Frame: From Baseline up to the last 35 days of treatment (up to Week 24)
|
A responder was a participant who had MBL volume of < 80 mL and at least a 50% reduction from baseline MBL volume over the last 35 days of treatment (up to Week 24). All returned feminine products collected at each clinical visit were analyzed by the alkaline hematin method to obtain the MBL volume. MBL volume was measured over the Week 24/early termination feminine product collection interval (up to 35 days prior to the last dose of treatment). The percentage of participants who were responders are presented. As per the objective of the study, the pre-specified primary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented. |
From Baseline up to the last 35 days of treatment (up to Week 24)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage Of Participants With A Hemoglobin Level ≤ 10.5 g/dL At Baseline Who Achieved An Increase Of > 2 g/dL From Baseline At Week 24
Time Frame: From Baseline up to Week 24
|
Blood samples were collected from participants for hemoglobin measurements. Percentages are based on number of participants with hemoglobin ≤ 10.5 gram (g)/deciliter (dL) at Baseline and reported at Week 24. As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA with placebo arms are presented. |
From Baseline up to Week 24
|
Percentage Of Participants Experiencing Vasomotor Symptoms Through Week 24
Time Frame: Baseline through Week 24
|
An adverse event was defined as an unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product, whether or not related to the medicinal product. The preferred terms of hyperhidrosis, feeling hot, hot flush, night sweats, and flushing were combined to describe vasomotor symptoms. Participants with multiple events for a given preferred term were counted only once for each preferred term. Reported percentages based on the total number of participants in each treatment group. As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented. |
Baseline through Week 24
|
Sustained Amenorrhea Rate (No Or Negligible Bleeding)
Time Frame: Week 24
|
Sustained amenorrhea is defined as participants time to achieve and maintain amenorrhea until the date of last study drug. As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented. |
Week 24
|
Time To Achieving Sustained Amenorrhea (No Or Negligible Bleeding)
Time Frame: From Baseline through Week 24
|
Sustained amenorrhea status as determined based on time to achieve and maintain amenorrhea status. As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented. |
From Baseline through Week 24
|
Time To Achieving Amenorrhea (No Or Negligible Bleeding)
Time Frame: From Baseline through Week 24
|
Time to amenorrhea was defined as the weeks from date of first dose of study drug to the start of amenorrhea. As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented. |
From Baseline through Week 24
|
Number Of Participants With Hemoglobin ≤ 10.5 g/dL At Baseline And Achieved An Increase Of > 2 g/dL At Week 24
Time Frame: From Baseline through Week 24
|
As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo.
Therefore, only relugolix plus E2/NETA and placebo arms are presented.
|
From Baseline through Week 24
|
Number Of Participants With Hemoglobin Increase Of ≥ 1 g/dL From Baseline To Week 24 Among Those With Below Lower Limit Of Normal
Time Frame: Week 24
|
As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo.
Therefore, only relugolix plus E2/NETA and placebo arms are presented.
|
Week 24
|
Number Of Responders With At Least 20 Points Increase From Baseline At Week 24 In UFS-QoL Revised Activities Scale Score
Time Frame: From Baseline through Week 24
|
As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo.
Therefore, only relugolix plus E2/NETA and placebo arms are presented.
|
From Baseline through Week 24
|
Change From Baseline At Week 24 In The Interference Of Uterine Fibroids With Physical Activities Based On UFS-QoL Question 11
Time Frame: Baseline, Week 24
|
Transformed score ranges from 0 to 100 based on Likert scale (None of time, a little of time, some of the time, most of the time and all of the time). Lower score indicates minimal symptom severity and higher score indicates maximum symptom severity. A negative change from baseline indicates improvement. As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented. |
Baseline, Week 24
|
Change From Baseline At Week 24 In The Interference Of Uterine Fibroids With Social Activities Based On UFS-QoL Question 20
Time Frame: Baseline, Week 24
|
Transformed score ranges from 0 to 100 based on Likert scale (None of time, a little of time, some of the time, most of the time and all of the time). Lower score indicates minimal symptom severity and higher score indicates maximum symptom severity. A negative change from baseline indicates improvement. As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented. |
Baseline, Week 24
|
Change From Baseline At Week 24 In Embarrassment Caused By Uterine Fibroids Based On UFS-QoL Question 29
Time Frame: Baseline, Week 24
|
Transformed score ranges from 0 to 100 based on Likert scale (None of time, a little of time, some of the time, most of the time and all of the time). Lower score indicates minimal symptom severity and higher score indicates maximum symptom severity. A negative change from baseline indicates improvement. As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented. |
Baseline, Week 24
|
Change From Baseline At Week 24 In The Menorrhagia Impact Questionnaire Score For Physical Activities
Time Frame: Baseline, Week 24
|
The Menorrhagia Impact was evaluated using a 5-point response scale to assess level of improvement from Baseline to Week 24. Response scale: Not at all, 2. Slightly, 3.Moderately, 4. Quite a bit and 5. Extremely. As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented. |
Baseline, Week 24
|
Change From Baseline At Week 24 In The Menorrhagia Impact Questionnaire Score For Social Activities
Time Frame: Baseline, Week 24
|
The Menorrhagia Impact was evaluated using a 5-point response scale to assess level of improvement from Baseline to Week 24. Response scale: Not at all, 2. Slightly, 3.Moderately, 4. Quite a bit and 5. Extremely. As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented. |
Baseline, Week 24
|
Number Of Participants Who Achieved A Maximum NRS Score ≤ 1 For Uterine Fibroid-associated Pain Over The Last 35 Days Of Treatment Who Had Maximum Pain Scores ≥ 4 During The 35 Days Prior To Randomization
Time Frame: From Baseline up to the last 35 days of treatment (up to 24 weeks)
|
Uterine fibroid-associated pain was assessed by a pain NRS. The pain NRS is a validated, single-item, self-reported measure, which asks respondents to rank their pain on an 11-point scale as follows: 0 (no pain), 1 to 3 (mild pain), 4 to 6 (moderate pain), and 7 to 10 (severe pain). As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented. |
From Baseline up to the last 35 days of treatment (up to 24 weeks)
|
Number Of Participants With A ≥ 30% Reduction in NRS Score From Baseline to Last 35 Days of Treatment Who Had Maximum Pain Scores ≥ 4 At Baseline
Time Frame: Baseline, Week 24
|
Uterine fibroid-associated pain was assessed by a pain NRS. The pain NRS is a validated, single-item, self-reported measure, which asks respondents to rank their pain on an 11-point scale as follows: 0 (no pain), 1 to 3 (mild pain), 4 to 6 (moderate pain), and 7 to 10 (severe pain). As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented. |
Baseline, Week 24
|
Change From Baseline In Luteinizing Serum Concentration At Week 24
Time Frame: Baseline, Week 24
|
As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo.
Therefore, only relugolix plus E2/NETA and placebo arms are presented.
|
Baseline, Week 24
|
Change From Baseline In Follicle Stimulating Serum Concentration At Week 24
Time Frame: Baseline, Week 24
|
As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo.
Therefore, only relugolix plus E2/NETA and placebo arms are presented.
|
Baseline, Week 24
|
Change From Baseline In E2 Serum Concentration At Week 24
Time Frame: Baseline, Week 24
|
As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo.
Therefore, only relugolix plus E2/NETA and placebo arms are presented.
|
Baseline, Week 24
|
Change From Baseline In Progesterone Serum Concentration At Week 24
Time Frame: Baseline, Week 24
|
As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo.
Therefore, only relugolix plus E2/NETA and placebo arms are presented.
|
Baseline, Week 24
|
Percentage Of Participants With Amenorrhea Over The Last 35 Days Of Treatment
Time Frame: From Baseline up to last 35 days of treatment (up to Week 24)
|
Amenorrhea was defined as meeting 1 of the following criteria for 2 consecutive visits:
As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented. |
From Baseline up to last 35 days of treatment (up to Week 24)
|
Percent Change From Baseline At Week 24 In MBL Volume
Time Frame: Baseline, Week 24
|
MBL volume was measured using the alkaline hematin method. Least square (LS) means for test of difference is Relugolix plus E2/NETA minus Placebo based on mixed-effect model with treatment, visit, region, Baseline MBL, and treatment by visit interaction included as fixed effects. As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented. |
Baseline, Week 24
|
Percentage Of Participants With A Maximum Numerical Rating Scale (NRS) Score ≤ 1 For Uterine Fibroid-Associated Pain Over The Last 35 Days Of Treatment
Time Frame: From Baseline up to Week 24
|
Uterine fibroid-associated pain was assessed by a pain numerical rating scale (NRS). The pain NRS is a validated, single-item, self-reported measure, which asks respondents to rank their pain on an 11-point scale as follows: 0 (no pain), 1 to 3 (mild pain), 4 to 6 (moderate pain), and 7 to 10 (severe pain). Participants were asked to document, in an e-Diary, the worst pain associated with their uterine fibroids that they experienced during the last 24 hours, every day until the end of study drug administration. Pain evaluable participants, defined as those who had maximum NRS score ≥ 4 at baseline and had at least 28 days (80% of the last 35 days of treatment) of pain scores recorded in the e-Diary, were analyzed. As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented. |
From Baseline up to Week 24
|
Percent Change From Baseline At Week 24 In Primary Uterine Fibroid Volume
Time Frame: Baseline Week 24
|
The volume of the primary uterine fibroid was measured by transvaginal or transabdominal ultrasound. As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented. |
Baseline Week 24
|
Percent Change From Baseline At Week 24 In Uterine Volume
Time Frame: From Baseline up to Week 24
|
The volume of the uterus was measured by transvaginal or transabdominal ultrasound. As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented. |
From Baseline up to Week 24
|
Change From Baseline At Week 24 In UFS-QoL Bleeding And Pelvic Discomfort Scale Score As Measured By The UFS-QoL (Q1, Q2, Q5)
Time Frame: Baseline Week 24
|
The Uterine Fibroid Symptom and Health-Related Quality of Life (UFS-QoL) Bleeding and Pelvic Discomfort (BPD) Scale has been derived from the UFS-QoL Symptoms Scale. The scale consists of the following 3 symptoms proximal to uterine fibroids: Heavy bleeding during your menstrual period (Question [Q] 1), passing blood clots during your menstrual period (Q2), and feeling tightness or pressure in your pelvic area (Q5), raw scores were transformed to a normalized score: Transformed Score = [(Actual raw score - lowest possible raw score)/(Possible raw score range)]*100 Transformed score ranges from 0 to 100 based on Likert scale (None of time, a little of time, some of the time, most of the time and all of the time). Lower score indicates minimal symptom severity and higher score indicates symptom severity. As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms |
Baseline Week 24
|
Percent Change From Baseline At Week 12 In Bone Mineral Density At The Lumbar Spine (L1 to L4) As Assessed By DXA
Time Frame: From Baseline up to Week 12
|
Bone mineral density (BMD) was assessed by dual-energy x-ray absorptiometry (DXA) at the lumbar spine (L1, L2, L3, and L4) at Baseline and at Week 12. The scans were read by the central radiology laboratory in accordance with the imaging charter. The same DXA machine was used at the local imaging center at each site and operated in the same scan mode for all images procured for an individual participant. All images were submitted for central reading. The central radiology laboratory collected and evaluated all DXA scans for acceptability and measured BMD. The LS means were based on a mixed-effect model with visit, region, Baseline MBL volume, age at Baseline, body mass index at Baseline, BMD at Baseline, race, and treatment by visit interaction included as fixed effects. As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented. |
From Baseline up to Week 12
|
Percent Change From Baseline At Week 24 In Bone Mineral Density At The Lumbar Spine (L1 To L4), Total Hip, And Femoral Neck As Assessed By DXA
Time Frame: Baseline through Week 24
|
BMD was assessed by DXA at the lumbar spine (L1, L2, L3, and L4), total hip, and femoral neck (same leg across participants) at Baseline and at Week 24. The scans were read by the central radiology laboratory in accordance with the imaging charter. The same DXA machine was used at the local imaging center at each site and operated in the same scan mode for all images procured for an individual participant. All images were submitted for central reading. The central radiology laboratory collected and evaluated all DXA scans for acceptability and measured BMD. The LS means were based on a mixed-effect model with visit, region, Baseline MBL volume, age at Baseline, body mass index at Baseline, BMD at Baseline, race, and treatment by visit interaction included as fixed effects. For Relugolix plus E2/NETA Lumbar Spine (L1 to L4), number (n)=95. As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only rel |
Baseline through Week 24
|
Percentage Of Participants Experiencing Vasomotor Symptoms Through Week 12
Time Frame: Baseline through Week 12
|
An adverse event was defined as an unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product, whether or not related to the medicinal product.
The preferred terms of hyperhidrosis, feeling hot, hot flush, night sweats, and flushing were combined to describe vasomotor symptoms.
Participants with multiple events for a given preferred term were counted only once for each preferred term.
Reported confidence interval (CI) based on exact binomial 95% CI (Clopper-Pearson).
As per the objective of the study, the secondary analysis compared relugolix plus E2/NETA with relugolix plus delayed E2/NETA at Week 12 and are presented below.
|
Baseline through Week 12
|
Predose Trough Concentrations Of Relugolix And NET In The Relugolix Plus E2/NETA Group At Week 24
Time Frame: Week 24
|
Blood samples for determination of relugolix and NET plasma concentrations were collected predose at Week 24. Relugolix and NET plasma concentrations were determined using validated bioanalytical methodology. Concentrations below the quantification limit (BQL) were set to 0 for analysis of summary statistics. As per the objective of the study, only relugolix plus E2/NETA concentration is presented. |
Week 24
|
Predose Trough Concentrations Of E2 In The Relugolix Plus E2/NETA Group At Week 24
Time Frame: Week 24
|
Blood samples for determination of relugolix and NET plasma concentrations were collected predose at Week 24. Relugolix and NET plasma concentrations were determined using validated bioanalytical methodology. Concentrations below the quantification limit (BQL) were set to 0 for analysis of summary statistics. As per the objective of the study, only relugolix plus E2/NETA concentration is presented. |
Week 24
|
Change From Baseline At Week 24 In Predose Concentrations Of E2 In The Relugolix Plus E2/NETA Group
Time Frame: Baseline, Week 24
|
Blood samples for determination of E2 serum concentrations were collected predose at Week 24. Relugolix and NET plasma concentrations were determined using validated bioanalytical methodology. Concentrations below the quantification limit (BQL) were set to 0 for analysis of summary statistics. As per the objective of the study, only relugolix plus E2/NETA concentration is presented. |
Baseline, Week 24
|
Time To MBL Response
Time Frame: From Baseline through Week 24
|
Defined as the time to achieve an MBL volume of < 80 mL and a ≥ 50% reduction from Baseline MBL volume as measured by the alkaline hematin method. As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented. |
From Baseline through Week 24
|
Percent Change From Baseline At Week 24 In Hemoglobin For Women With A Hemoglobin Concentration ≤ 10.5 g/dL At Baseline
Time Frame: Baseline, Week 24
|
As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo.
Therefore, only relugolix plus E2/NETA and placebo arms are presented.
|
Baseline, Week 24
|
Change From Baseline At Week 24 In The UFS-QoL Symptom Severity Scale Score
Time Frame: Baseline, Week 24
|
Transformed score ranges from 0 to 100 based on Likert scale (None of time, a little of time, some of time, most of the time and all of the time.) Lower score indicates minimal symptom severity and higher score indicates maximum symptom severity. A negative change from baseline indicates improvement. As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented. |
Baseline, Week 24
|
Change From Baseline At Week 24 In The UFS-QoL Activities Scale Score
Time Frame: Baseline, Week 24
|
Transformed score ranges from 0 to 100 based on Likert scale (None of time, a little of time, some of the time, most of the time and all of the time). Higher scores are indicative of better health-related quality of life (high score = good). As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented. |
Baseline, Week 24
|
Change From Baseline At Week 24 In The UFS-QoL Revised Activities Scale Score
Time Frame: Baseline, Week 24
|
Transformed score ranges from 0 to 100 based on Likert scale (none of time, a little of time, some of the time, most of the time and all of the time). Higher scores are indicative of better health-related quality of life (high score = good). LS means and p-value for test of difference was relugolix plus E2/NETA minus placebo based on mixed-effect model with treatment, visit, region, Baseline MBL and treatment by visit interaction included as fixed effects. As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented. |
Baseline, Week 24
|
Change From Baseline In UFS-QoL Score by Health-Related Quality of Life Total Score
Time Frame: Baseline, Week 24
|
The UFS-QoL total score was the sum of 6 subscales (concern, activities, energy/mood, control, self-conscious, and sexual function). The raw scores were transformed to normalized scores. Transformed score ranges from 0 to 100. Higher scores are indicative of better health-related quality of life (high = good). As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented. |
Baseline, Week 24
|
Change From Baseline in UFS-QoL Bleeding and Pelvic Discomfort Scale Score
Time Frame: Baseline, Week 24
|
The Bleeding and Pelvic Discomfort Scale consists of 3 items proximal to uterine fibroids that are experienced by most participants (heavy bleeding during the menstrual period [Question 1], passing blood clots during the menstrual period [Question 2], and feeling tightness or pressure in the pelvic area [Question 5]).Transformed score ranges from 0 to 100 based on Likert scale (None of time, a little of time, some of the time, most of the time and all of the time). Lower score indicates minimal symptom severity and higher score indicates maximum symptom severity. A negative change from baseline indicates improvement. As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented. |
Baseline, Week 24
|
Number Of Responders With At Least 20 Points Decrease in UFS-QoL Bleeding And Pelvic Discomfort Scale Score
Time Frame: Baseline, Week 24
|
Responder was defined as meeting a meaningful change threshold, set as a 20-point change from Baseline, in the Bleeding And Pelvic Discomfort Scale at Week 24 on the transformed score. As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented. |
Baseline, Week 24
|
Change From Baseline At Week 24 In Symptoms Assessed Using The Patient Global Assessment (PGA) Questionnaire
Time Frame: Baseline, Week 24
|
PGAs assessed participants' limitation in activities and the severity of symptoms due to uterine fibroids over the previous 4 weeks, as perceived by the participant. The PGA for symptoms is a 1-item questionnaire designed to assess participant's impression of the severity of their symptoms related to uterine fibroids. The PGA for function and symptoms was evaluated using a 5-point response scale (no limitation at all [1], mild limitation [2], moderate limitation [3], quite a bit of limitation [4], and extreme limitation [5]). As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented. |
Baseline, Week 24
|
Change From Baseline At Week 24 In Function Assessed Using The PGA Questionnaire
Time Frame: Baseline, Week 24
|
PGAs assessed participants' limitation in activities and the severity of symptoms due to uterine fibroids over the previous 4 weeks, as perceived by the participant. The PGA for symptoms is a 1-item questionnaire designed to assess participant's impression of the severity of their symptoms related to uterine fibroids. The PGA for function and symptoms was evaluated using a 5-point response scale (no limitation at all [1], mild limitation [2], moderate limitation [3], quite a bit of limitation [4], and extreme limitation [5]). As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented. |
Baseline, Week 24
|
Participants Achieving Improvement From Baseline In PGA Questionnaire For Symptoms From Baseline At Week 24
Time Frame: From Baseline through Week 24
|
The PGAs assessed participants' limitation in activities and the severity of symptoms due to uterine fibroids over the previous 4 weeks, as perceived by the participant. The PGA for function and symptoms was evaluated using a 5-point response scale (no limitation at all [1], mild limitation [2], moderate limitation [3], quite a bit of limitation [4], and extreme limitation [5]). Category improvements for symptoms are presented. A 1-category improvement would be severe at baseline to moderate. As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented. |
From Baseline through Week 24
|
Participants Achieving Improvement From Baseline In PGA For Uterine Fibroid-related Function From Baseline At Week 24
Time Frame: From Baseline through Week 24
|
The PGAs assessed participants' limitation in activities and the severity of symptoms due to uterine fibroids over the previous 4 weeks, as perceived by the participant. The PGA for function and symptoms was evaluated using a 5-point response scale (no limitation at all [1], mild limitation [2], moderate limitation [3], quite a bit of limitation [4], and extreme limitation [5]). Category improvements for symptoms are presented. A 1-category improvement would be severe at Baseline to moderate. As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented. |
From Baseline through Week 24
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Al-Hendy A, Lukes AS, Poindexter AN 3rd, Venturella R, Villarroel C, McKain L, Li Y, Wagman RB, Stewart EA. Long-term Relugolix Combination Therapy for Symptomatic Uterine Leiomyomas. Obstet Gynecol. 2022 Dec 1;140(6):920-930. doi: 10.1097/AOG.0000000000004988. Epub 2022 Nov 2.
- Stewart EA, Lukes AS, Venturella R, Arjona Ferreira JC, Li Y, Hunsche E, Wagman RB, Al-Hendy A. Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials. Obstet Gynecol. 2022 Jun 1;139(6):1070-1081. doi: 10.1097/AOG.0000000000004787. Epub 2022 May 2. Erratum In: Obstet Gynecol. 2022 Jul 1;140(1):138.
- Hunsche E, Rakov V, Scippa K, Witherspoon B, McKain L. The Burden of Uterine Fibroids from the Perspective of US Women Participating in Open-Ended Interviews. Womens Health Rep (New Rochelle). 2022 Mar 4;3(1):286-296. doi: 10.1089/whr.2021.0086. eCollection 2022.
- Al-Hendy A, Lukes AS, Poindexter AN 3rd, Venturella R, Villarroel C, Critchley HOD, Li Y, McKain L, Arjona Ferreira JC, Langenberg AGM, Wagman RB, Stewart EA. Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy. N Engl J Med. 2021 Feb 18;384(7):630-642. doi: 10.1056/NEJMoa2008283.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Uterine Diseases
- Connective Tissue Diseases
- Neoplasms, Connective Tissue
- Menstruation Disturbances
- Neoplasms, Muscle Tissue
- Uterine Hemorrhage
- Hemorrhage
- Leiomyoma
- Myofibroma
- Menorrhagia
- Physiological Effects of Drugs
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Estrogens
- Hormone Antagonists
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptives, Oral
- Contraceptive Agents, Female
- Contraceptives, Oral, Synthetic
- Contraceptives, Oral, Hormonal
- Androgen Antagonists
- Estradiol
- Estradiol 17 beta-cypionate
- Estradiol 3-benzoate
- Polyestradiol phosphate
- Norethindrone
- Norethindrone Acetate
- Relugolix
Other Study ID Numbers
- MVT-601-3002
- 2016-005113-50 (EUDRACT_NUMBER)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Uterine Fibroid
-
Johns Hopkins UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingLeiomyoma | Fibroid Uterus | Leiomyoma, Uterine | Fibroid Tumor | FibromyomaUnited States
-
Kangbuk Samsung HospitalUnknownUterine FibroidKorea, Republic of
-
Ain Shams Maternity HospitalCompleted
-
Unity Health TorontoCompleted
-
Northwestern UniversityCompletedEndometriosis | Uterine Fibroid | Uterine Adenomyosis | Endometrial Cyst | Fibroid Uterus | Uterus Myoma | Uterine CystUnited States
-
University of California, San FranciscoEunice Kennedy Shriver National Institute of Child Health and Human Development...Not yet recruitingLeiomyoma | Fibroid | Fibroid Uterus | Leiomyoma, UterineUnited States
-
Mansoura UniversityCompletedCesarean Section | Uterine Fibroid
-
West China Second University HospitalActive, not recruitingUterine Sarcoma | Uterine Fibroid | Uterine LeiomyosarcomaChina
-
Actamax Surgical Materials LLCNot yet recruiting
-
EgymedicalpediaCompleted
Clinical Trials on Relugolix placebo
-
TakedaCompleted
-
Yale UniversityPfizerRecruiting
-
TakedaCompleted
-
University of OklahomaNot yet recruitingAndrogen Deprivation Therapy | Locally Advanced Prostate CancerUnited States
-
Sumitomo Pharma Switzerland GmbHActive, not recruiting
-
Sumitomo Pharma Switzerland GmbHRecruitingPregnancy Complications | Pregnancy Related | Pregnancy, High RiskUnited States
-
TakedaCompleted
-
University of MiamiVarian Medical SystemsNot yet recruiting
-
Sumitomo Pharma Switzerland GmbHRecruitingEndometriosis | Uterine FibroidsUnited States
-
ASKA Pharmaceutical Co., Ltd.Completed